Next Article in Journal
Evidence for Anti-Viral Effects of Complete Freund’s Adjuvant in the Mouse Model of Enterovirus Infection
Previous Article in Journal
Japan’s Ongoing Crisis on HPV Vaccination
Article

Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates

1
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
2
Department of Parasitology, Biomedical Primate Research Centre (BPRC), 2288 GJ Rijswijk, The Netherlands
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Vaccines 2020, 8(3), 363; https://doi.org/10.3390/vaccines8030363
Received: 15 June 2020 / Revised: 2 July 2020 / Accepted: 3 July 2020 / Published: 6 July 2020
(This article belongs to the Section Vaccines against Infectious Diseases)
Plasmodium vivax is the world’s most widely distributed human malaria parasite, with over 2.8 billion people at risk in Asia, the Americas, and Africa. The 80–90% new P. vivax malaria infections are due to relapses which suggest that a vaccine with high efficacy against relapses by prevention of hypnozoite formation could lead to a significant reduction in the prevalence of P. vivax infections. Here, we describe the development of new recombinant ChAdOx1 and MVA vectors expressing P. cynomolgi Thrombospondin Related Adhesive Protein (PcTRAP) and the circumsporozoite protein (PcCSP). Both were shown to be immunogenic in mice prior to their assessment in rhesus macaques. We confirmed good vaccine-induced humoral and cellular responses after prime-boost vaccination in rhesus macaques prior to sporozoite challenge. Results indicate that there were no significant differences between mock-control and vaccinated animals after challenge, in terms of protective efficacy measured as the time taken to 1st patency, or as number of relapses. This suggests that under the conditions tested, the vaccination with PcTRAP and PcCSP using ChAdOx1 or MVA vaccine platforms do not protect against pre-erythrocytic malaria or relapses despite good immunogenicity induced by the viral-vectored vaccines. View Full-Text
Keywords: P. vivax; Circumsporozoite protein; CSP; thrombospondin related adhesive protein: TRAP; adenoviruses; MVA; malaria; vaccines P. vivax; Circumsporozoite protein; CSP; thrombospondin related adhesive protein: TRAP; adenoviruses; MVA; malaria; vaccines
Show Figures

Figure 1

MDPI and ACS Style

Kim, Y.C.; Dema, B.; Rodriguez-Garcia, R.; López-Camacho, C.; Leoratti, F.M.S.; Lall, A.; Remarque, E.J.; Kocken, C.H.M.; Reyes-Sandoval, A. Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines 2020, 8, 363. https://doi.org/10.3390/vaccines8030363

AMA Style

Kim YC, Dema B, Rodriguez-Garcia R, López-Camacho C, Leoratti FMS, Lall A, Remarque EJ, Kocken CHM, Reyes-Sandoval A. Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines. 2020; 8(3):363. https://doi.org/10.3390/vaccines8030363

Chicago/Turabian Style

Kim, Young C., Barbara Dema, Roberto Rodriguez-Garcia, César López-Camacho, Fabiana M.S. Leoratti, Amar Lall, Edmond J. Remarque, Clemens H.M. Kocken, and Arturo Reyes-Sandoval. 2020. "Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates" Vaccines 8, no. 3: 363. https://doi.org/10.3390/vaccines8030363

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop